Ratings Surperformance

Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-

Ratings ESG MSCI

Ratings Diaceutics PLC: Strengths and Weaknesses

Highlights: Diaceutics PLC
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses: Diaceutics PLC
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • The group usually releases earnings worse than estimated.

Rating Financials

Diaceutics PLC SectorUnited States

Fundamentals

-

Growth

Revenue growth

EPS growth

-

FCF growth

Profitability

EBITDA Margin

EBIT Margin

Net Margin

Capital Efficiency

-

ROA

-

ROCE

-

ROE

-

Financial Health

-

Gearing

-

Leverage

Capital Intensity

Balance sheet growth

-

Long Term balance sheet growth

-

Long term revenue growth

Long term EPS growth

-
More ratings

Rating Valuation

Diaceutics PLC SectorUnited States

Global Valuation

-

Enterprise Value

EV/Revenue

EV/EBITDA

EV/FCF

-

Equity Valuation

-

P/E

-

PBR

Dividend Yield

-

EV/EBIT

CAPEX/Revenue

More ratings

Rating Consensus

Diaceutics PLC SectorUnited States

Consensus

Analysts' buy/sell recommendations

Analysts' recommendations evolution (1 year)

Analysts' recommendations evolution (4 months)

Analysts' target price

Analysts' target price evolution (1 year)

Analysts' target price evolution (4 months)

Analysts' recommendations evolution (7 days)

Target Price evolution (7 days)

More ratings

Rating Business Predictability

Diaceutics PLC SectorUnited States

Visibility

Analysts' coverage

Financial estimates divergence

Analysts' recommendations divergence

Analysts' Target price divergence

Surprise rates

Rating Revisions

Diaceutics PLC SectorUnited States

Financial revisions

Revenue revisions (1 year)

Revenue revisions (4 months)

EPS revisions (1 year)

EPS revisions (4 months)

EPS revisions (7 days)

Revenue revisions (7 days)

More ratings

Capi.($) Investor ESG MSCI Fundamentals Financial revisions Global Valuation Visibility Consensus
162M - - - -
59.49B
AA
-
3.94B -
3.28B -
1.35B - - - - - - -
1.3B - - - -
1.22B
BBB
1.13B - - - - -
1.07B
BBB
Average 8.11B
A
Weighted average by Cap.
A
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!